LL-37 (CAP-18)

Description

Overview of LL-37 (derived from CAP-18) 

The synthetic LL-37 is a lab-made version of the human antimicrobial peptide LL-37. It is manufactured to replicate the natural amino-acid sequence of the endogenous peptide derived from CAP-18. 

LL-37 is the active peptide fragment that is generated when CAP-18 is enzymatically cleaved. Furthermore, studies indicate that LL-37 is derived from the C-terminal portion of CAP-18 and contains 37 amino acids.

In modern research settings,LL-37 is being studied for its role in innate immune responses and antimicrobial mechanisms in preclinical models. Researchers also investigate this peptide for its potential involvement in inflammatory signaling and tissue-related processes in preclinical models.

Note:LL-37 is not approved by the U.S. Food and Drug Administration for any therapeutic use. It is primarily recognized as a research peptide. We sell it only for lab research purposes. It is not intended for human or animal use.

Chemical and Molecular Properties

Property	Details
Name	LL-37
PubChem CID	16198951
Molecular Formula	C205H340N60O53
Molecular Weight	4493.0 g/mol
Source	Endogenous peptide (human-derived sequence)
Major Constituents	LL-37 peptide chain
CAS	144097-81-6
Labeling	Research Use Only (RUO)
IUPAC Condensed	H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH
Chemical Structure Depiction
Purity	>98%
Classification	Research Use Only (RUO)
Storage Temperature	–20 °C recommended; avoid repeated freeze-thaw cycles
Solubility	Soluble in water or buffer systems; pH-dependent
Safety	Handle using standard laboratory practices; follow institutional biosafety guidelines.

Proposed Working Mechanism of LL-37 [CAP-18]

Researchers have observed that LL-37 exhibits membrane-active properties in vitro. Studies have reported that it may bind to negatively charged microbial surfaces and interact with lipid bilayers. 

Additionally, Laboratory studies have suggested that LL-37 may alter membrane structure and influence fluidity. It has also been studied for its role in peptide–membrane interactions as observed by researchers in a few laboratory models.

Moreover,LL-37 has been studied for interactions with signaling molecules that regulate inflammatory pathways. These studies include LL-37’s effects on cytokine and chemokine production in cell-based research preclinical models. 

Possible Research Applications of LL-37 [CAP-18]

LL-37 is studied in molecular research for the following:

• Study membrane-disrupting peptides and peptide-lipid interactions.
• Explore signaling pathways related to inflammation.
• Investigate mechanisms associated with angiogenesis in vitro.
• Examine immune-related molecular interactions.

Why Choose Purerawz for LL-37?

Buy LL-37 for laboratory research use from our online shop. At Purerawz, we provide high-quality reference materials. Each research compound comes with a Certificate of Analysis for verification of purity and concentration.

Note:

LL-37  is an investigational compound currently undergoing clinical evaluation and has not been established as safe or effective for any therapeutic use

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

Reference Links

• PubChem. (n.d.-u). PubChem. PubChem. https://pubchem.ncbi.nlm.nih.gov/#query=LL-37
• Burton, M. F., & Steel, P. G. (2009). The chemistry and biology of LL-37. Natural Product Reports, 26(12), 1572. https://doi.org/10.1039/b912533g
• Bucki, R., Leszczyńska, K., Namiot, A., & Sokołowski, W. (2010). Cathelicidin LL-37: A multitask antimicrobial peptide.Archivum Immunologiae Et Therapiae Experimentalis,58(1), 15–25. https://doi.org/10.1007/s00005-009-0057-2